GlycoBac has developed a sensitive assay for infectious Sf-rhabdovirus particles using our proprietary Sf-RVN cell line. GlycoBac has partnered with MilliporeSigma to facilitate the distribution of our Sf-RVN cell line for commercial vaccine and gene therapy vector production. In addition to distributing Sf-RVN cells through a cGMP cell bank, MilliporeSigma will offer a chemically defined medium formulation specially designed for Sf-RVN cells.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Nationally (across the country)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
GlycoBac study highlighted inVirology
GlycoBac researchers recently published a peer-reviewed study on genetic variation and infectivity of Sf-rhabdovirus from different Sf cell lines in the December issue of Virology (Vol. 512, pp. 234-245)
This is the first published study to directly demonstrate Sf-rhabdoviruses can establish persistent, productive infections in Sf cells. It is also the first study to directly demonstrate different Sf-rhabdovirus variants, including variants with a large deletion, are infectious in Sf cells.
The editors of Virology chose to highlight this study. In addition, we were invited to post a synopsis of our study on the Virology Highlights blog.
We thank the editors for recognizing the value of our work!
Sf-RVN cells are a safer alternative to commonly used S. frugiperda cell lines. Listen to Prof. Dr. Jarvis talk about Sf-RVN cells and how they compare to Sf9 cells.